{"doi":"10.1159/000337400","title":"The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer","abstract":null,"journal":"Onkologie","year":2012,"id":687364,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1795696,"name":"Mika Kitagawa","orcid":null,"position":1,"is_corresponding":false},{"id":132558,"name":"Tomonori Yamada","orcid":null,"position":2,"is_corresponding":false},{"id":1795697,"name":"Michihiro Yoshida","orcid":null,"position":3,"is_corresponding":false},{"id":1795699,"name":"Masahide Ebi","orcid":null,"position":4,"is_corresponding":false},{"id":1795701,"name":"Yoshikazu Hirata","orcid":null,"position":5,"is_corresponding":false},{"id":1795702,"name":"Takashi Mizushima","orcid":null,"position":6,"is_corresponding":false},{"id":1795703,"name":"Tsutomu Mizoshita","orcid":null,"position":7,"is_corresponding":false},{"id":1795704,"name":"Satoshi Tanida","orcid":null,"position":8,"is_corresponding":false},{"id":1539773,"name":"Hiromi Kataoka","orcid":null,"position":9,"is_corresponding":false},{"id":1795706,"name":"Takeshi Kamiya","orcid":null,"position":10,"is_corresponding":false},{"id":1539774,"name":"Takashi Joh","orcid":null,"position":11,"is_corresponding":false},{"id":1795695,"name":"Takaya Shimura","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer","abstract":"BACKGROUND: Paclitaxel and docetaxel show similar anticancer mechanisms, but cross-resistance for gastric cancer chemotherapy remains unclear. PATIENTS AND METHODS: Among 484 patients with metastatic gastric cancer, who had received chemotherapy in 4 Japanese hospitals, we identified 28 patients who had received either paclitaxel- or docetaxel-containing chemotherapy and who were refractory to the other taxane. RESULTS: The median age was 65 years, and target lesions were present in 20 patients and absent in 8. The first taxane was administered to 16 patients as first-line chemotherapy and to 12 patients as second-line chemotherapy, while the second taxane was administered to 5 patients as second-line, 13 as third-line, and 10 as fourth-line or beyond. The median survival time was 456 days (95% confidence interval (CI) 145-767 days), and the median survival time and median progression-free survival after the second taxane were 119 days (95% CI 85-153 days) and 50 days (95% CI 42-58 days), respectively. The second taxane chemotherapy achieved a response rate of 5% (1/20 patients) and an overall disease control rate of 17.9% (5/28 patients). CONCLUSIONS: Paclitaxel and docetaxel might show a large degree of cross-resistance for gastric cancer. Paclitaxel and docetaxel should not be routinely administered for metastatic gastric cancer after failure of the other taxane.","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22488087","pmcid":null,"openalex_id":"https://openalex.org/W1975820693","authors":[],"funders":[],"total_grants":0,"fwci":0.437,"citation_percentile":0.67238064,"influential_citations":0,"citation_trend":[{"year":2013,"count":2},{"year":2017,"count":2},{"year":2020,"count":1},{"year":2021,"count":1},{"year":2024,"count":2},{"year":2025,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.karger.com/Article/Pdf/337400","host_type":"publisher"},{"url":"https://doi.org/10.1159/000337400","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22488087","host_type":"repository"}],"fields_of_study":["Gastric Cancer Management and Outcomes","Helicobacter pylori-related gastroenterology studies","Colorectal Cancer Treatments and Studies"],"mesh_terms":["Docetaxel","Aged","Antineoplastic Agents","Female","Humans","Japan","Male","Risk Factors","Stomach Neoplasms","Prevalence","Survival Rate","Survival Analysis","Treatment Outcome","Paclitaxel","Risk Assessment","Drug Resistance, Neoplasm","Taxoids"],"keywords":["Docetaxel","Taxane","Paclitaxel","Medicine","Chemotherapy","Internal medicine","Oncology","Cancer","Metastatic breast cancer","Gastroenterology","Breast cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T21:51:11.527302Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}